These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 33550691)

  • 61. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
    Malone JK; Kerr LF; Campaigne BN; Sachson RA; Holcombe JH;
    Clin Ther; 2004 Dec; 26(12):2034-44. PubMed ID: 15823767
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Metformin reduces the relapse rate of tuberculosis patients with diabetes mellitus: experiences from 3-year follow-up.
    Ma Y; Pang Y; Shu W; Liu YH; Ge QP; Du J; Li L; Gao WW
    Eur J Clin Microbiol Infect Dis; 2018 Jul; 37(7):1259-1263. PubMed ID: 29679254
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Effect of metformin-containing antidiabetic regimens on all-cause mortality in veterans with type 2 diabetes mellitus.
    Gosmanova EO; Canada RB; Mangold TA; Rawls WN; Wall BM
    Am J Med Sci; 2008 Sep; 336(3):241-7. PubMed ID: 18794619
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial.
    Lund SS; Tarnow L; Stehouwer CD; Schalkwijk CG; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag A
    Diabetes Obes Metab; 2007 May; 9(3):394-407. PubMed ID: 17391168
    [TBL] [Abstract][Full Text] [Related]  

  • 65. How are patients with type 2 diabetes and renal disease monitored and managed? Insights from the observational OREDIA study.
    Penfornis A; Blicklé JF; Fiquet B; Quéré S; Dejager S
    Vasc Health Risk Manag; 2014; 10():341-52. PubMed ID: 24966684
    [TBL] [Abstract][Full Text] [Related]  

  • 66. First 20 months' experience with use of metformin for type 2 diabetes in a large health maintenance organization.
    Selby JV; Ettinger B; Swain BE; Brown JB
    Diabetes Care; 1999 Jan; 22(1):38-44. PubMed ID: 10333901
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.
    Halimi S; Le Berre MA; Grangé V
    Diabetes Res Clin Pract; 2000 Sep; 50(1):49-56. PubMed ID: 10936668
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Antithrombotic effects of rosiglitazone-metformin versus glimepiride-metformin combination therapy in patients with type 2 diabetes mellitus and metabolic syndrome.
    Derosa G; Gaddi AV; Piccinni MN; Ciccarelli L; Salvadeo S; Peros E; Ghelfi M; Ferrari I; Cicero AF
    Pharmacotherapy; 2005 May; 25(5):637-45. PubMed ID: 15899724
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Impact of metformin on the risk and treatment outcomes of tuberculosis in diabetics: a systematic review.
    Yu X; Li L; Xia L; Feng X; Chen F; Cao S; Wei X
    BMC Infect Dis; 2019 Oct; 19(1):859. PubMed ID: 31623569
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Analysis of the Adherence and Safety of Second Oral Glucose-Lowering Therapy in Routine Practice From the Mediterranean Area: A Retrospective Cohort Study.
    Vlacho B; Mata-Cases M; Mundet-Tudurí X; Vallès-Callol JA; Real J; Farre M; Cos X; Khunti K; Mauricio D; Franch-Nadal J
    Front Endocrinol (Lausanne); 2021; 12():708372. PubMed ID: 34335477
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The effect of vitamin C and/or E supplementations on type 2 diabetic adult males under metformin treatment: A single-blinded randomized controlled clinical trial.
    El-Aal AA; El-Ghffar EAA; Ghali AA; Zughbur MR; Sirdah MM
    Diabetes Metab Syndr; 2018 Jul; 12(4):483-489. PubMed ID: 29571976
    [TBL] [Abstract][Full Text] [Related]  

  • 72. A case risk study of lactic acidosis risk by metformin use in type 2 diabetes mellitus tuberculosis coinfection patients.
    Novita BD; Pranoto A; Wuryani ; Soediono EI; Mertaniasih NM
    Indian J Tuberc; 2018 Jul; 65(3):252-256. PubMed ID: 29933869
    [TBL] [Abstract][Full Text] [Related]  

  • 73. A Prospective Study of the Clinical and Demographic Profile of Type 2 Diabetes Mellitus Patients Receiving Antidiabetic Drug Combinations.
    Gadgade A; Kudgi AS; Kamath A; Kamath P; Adhikari P; Revappala NS; Hadigal S; Natarajan S; Shenoy N; Chowta MN
    Curr Diabetes Rev; 2020; 16(5):503-508. PubMed ID: 31250763
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
    Lancet; 1998 Sep; 352(9131):854-65. PubMed ID: 9742977
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Glycemic Efficacy and Metabolic Consequences of an Empagliflozin Add-on versus Conventional Dose-Increasing Strategy in Patients with Type 2 Diabetes Inadequately Controlled by Metformin and Sulfonylurea.
    Shin Y; Moon JH; Chin HJ; Ferrannini E; Lim S
    Endocrinol Metab (Seoul); 2020 Jun; 35(2):329-338. PubMed ID: 32615717
    [TBL] [Abstract][Full Text] [Related]  

  • 76. The use of metformin for type 2 diabetes prevention: Observational multicenter study from Saudi Arabia.
    Alfayez OM; Alsallum AA; Aljabri AF; Almutairi FS; Al-Azzeh O; Almalki OS; Al Yami MS; Almohammed OA
    Front Public Health; 2022; 10():989072. PubMed ID: 36159298
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Therapeutic efficacy and safety of initial triple combination of metformin, sitagliptin, and lobeglitazone in drug-naïve patients with type 2 diabetes: initial triple study.
    Lim S; Ku EJ; Lee SY; Lee JH; Lee JE; Kim KM; Davies MJ
    BMJ Open Diabetes Res Care; 2020 Jan; 8(1):. PubMed ID: 31958303
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial.
    Fonseca V; Rosenstock J; Patwardhan R; Salzman A
    JAMA; 2000 Apr; 283(13):1695-702. PubMed ID: 10755495
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Nateglinide and glibenclamide metabolic effects in naïve type 2 diabetic patients treated with metformin.
    Derosa G; D'Angelo A; Fogari E; Salvadeo S; Gravina A; Ferrari I; Cicero AF
    J Clin Pharm Ther; 2009 Feb; 34(1):13-23. PubMed ID: 19125899
    [TBL] [Abstract][Full Text] [Related]  

  • 80. [Efficacy and safety of the use of metformin in patients with chronic heart failure and type 2 diabetes mellitus. results of the study "rational effective mulicomponent therapy in the battle against diabetes mellitus in patients with chronic heart failure"].
    Lapina IuV; Narusov OIu; Mareev VIu; Bolotina MG; Shestakova MV; Masenko VP; Litonova GN; Arzamastseva NE; Baklanova NA; Belenkov IuN
    Kardiologiia; 2008; 48(3):58-68. PubMed ID: 18429758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.